Trial Profile

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRTX-1001 (Primary)
Indications Temporal-lobe-epilepsy
Focus Adverse reactions
Sponsors Neurona Therapeutics

Most Recent Events

09 Apr 2025 Planned End Date changed from 15 Jul 2040 to 15 Jun 2042.
09 Apr 2025 Planned primary completion date changed from 15 Jul 2026 to 15 Jun 2027.
08 Apr 2025 According to a Neurona Therapeutics media release, company presented updated data from this trial at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego, CA.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com